Zentalis Pharmaceuticals, Inc. Share Price
Stocks
ZNTL
US98943L1070
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
01:30:00 24/10/2026 am IST
|
5-day change | 1st Jan Change | ||
| 2.210 USD | -8.30% |
|
+3.76% | +63.70% |
| Market Cap | 21Cr 19Cr 17Cr 16Cr 29Cr 1.99TCr 30Cr 207.58Cr 82Cr 1.04TCr 79Cr 77Cr 3.28TCr | P/E 2026 * |
-1.07x | P/E 2027 * | -1.16x |
|---|---|---|---|---|---|
| Enterprise Value | 46.75L 41.71L 38.54L 34.98L 65.52L 44Cr 66.53L 4.64Cr 1.83Cr 23Cr 1.75Cr 1.72Cr 73Cr | EV / Sales 2026 * |
-
| EV / Sales 2027 * | 7.1x |
| Free-Float |
78.15% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| ZNTL | Delayed | |
CBOE
| ZNTL | Real-time |
Last Transcript: Zentalis Pharmaceuticals, Inc.
| 1 day | -8.30% | ||
| 1 week | +3.76% | ||
| Current month | -20.22% | ||
| 1 month | -18.15% | ||
| 3 months | -48.96% | ||
| 6 months | -44.47% | ||
| Current year | +63.70% |
| 1 week | 2.18 |  | 2.47 |
| 1 month | 2.07 | | 2.84 |
| Current year | 1.32 | | 6.95 |
| 1 year | 1.21 | | 6.95 |
| 3 years | 1.01 | | 18.24 |
| 5 years | 1.01 | | 87.19 |
| 10 years | 1.01 | | 87.19 |
| Manager | Title | Age | Since |
|---|---|---|---|
Julia Eastland
CEO | Chief Executive Officer | 62 | 13/11/2024 |
| Director of Finance/CFO | - | 13/11/2024 | |
Ingmar Bruns
CTO | Chief Tech/Sci/R&D Officer | 51 | 13/11/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
David Johnson
CHM | Chairman | 61 | 16/05/2022 |
Enoch Kariuki
BRD | Director/Board Member | 44 | 09/02/2021 |
Jan Skvarka
BRD | Director/Board Member | 59 | 12/09/2022 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 30/09/26 | Free | Chief Technology Officer | 9,727 | 0.0103% | ||
| 14/08/26 | Buy | 43,35,000 | 4.5791% | |||
| 26/05/26 | Free | Director | 1,14,200 | 0.1604% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -8.30% | +3.76% | +29.24% | -86.19% | 21Cr | |
| +2.41% | +0.29% | +39.41% | +72.14% | 6.47TCr | |
| -0.15% | +7.50% | +11.42% | +75.22% | 5.48TCr | |
| +0.57% | +4.60% | +7.71% | +90.93% | 5.35TCr | |
| +0.37% | +4.67% | +26.68% | +54.16% | 4.6TCr | |
| -1.21% | +2.32% | +21.50% | +126.83% | 4.29TCr | |
| -0.37% | +5.07% | +243.23% | +834.48% | 4.01TCr | |
| +0.05% | +0.21% | +18.06% | +48.50% | 3.35TCr | |
| +1.19% | -4.98% | +26.31% | -0.76% | 2.4TCr | |
| -0.38% | +5.68% | +38.39% | +28.35% | 2.37TCr | |
| Average | -0.58% | +2.55% | +46.19% | +124.37% | 3.83TCr | |
| Weighted average by Cap. | +0.39% | +2.73% | +46.01% | +149.46% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | 98.23L 87.65L 80.98L 73.5L 1.38Cr 93Cr 1.4Cr 9.75Cr 3.85Cr 49Cr 3.69Cr 3.61Cr 154.14Cr |
| Net income | -16Cr -14Cr -13Cr -12Cr -23Cr -1.54TCr -23Cr -161.16Cr -64Cr -808.21Cr -61Cr -60Cr -2.55TCr | -18Cr -16Cr -15Cr -13Cr -25Cr -1.7TCr -25Cr -177.32Cr -70Cr -889.27Cr -67Cr -66Cr -2.8TCr |
| Net Debt | -20Cr -18Cr -17Cr -15Cr -29Cr -1.94TCr -29Cr -202.94Cr -80Cr -1.02TCr -77Cr -75Cr -3.21TCr | -14Cr -12Cr -11Cr -10Cr -20Cr -1.32TCr -20Cr -138.36Cr -55Cr -693.9Cr -52Cr -51Cr -2.19TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/26/23 | $2.210 | -8.30% | 9,47,073 |
| 22/26/22 | $2.410 | +2.12% | 7,46,228 |
| 21/26/21 | $2.360 | -1.26% | 12,07,187 |
| 20/26/20 | $2.390 | +3.91% | 15,57,947 |
| 19/26/19 | $2.300 | +7.98% | 27,36,606 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ZNTL Stock
Select your edition
All financial news and data tailored to specific country editions
